Roxana Daneshjou
Roxana Daneshjou
MD/Ph.D, Dermatology Clinical Scholar, Stanford University
Verified email at
Cited by
Cited by
Data-driven prediction of drug effects and interactions
NP Tatonetti, PY Patrick, R Daneshjou, RB Altman
Science translational medicine 4 (125), 125ra31-125ra31, 2012
Bioinformatics challenges for personalized medicine
GH Fernald, E Capriotti, R Daneshjou, KJ Karczewski, RB Altman
Bioinformatics 27 (13), 1741-1748, 2011
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study
MA Perera, LH Cavallari, NA Limdi, ER Gamazon, A Konkashbaev, ...
The Lancet 382 (9894), 790-796, 2013
KJ Karczewski, R Daneshjou, RB Altman
PLoS Comput Biol 8 (12), e1002817, 2012
Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans
R Daneshjou, ER Gamazon, B Burkley, LH Cavallari, JA Johnson, ...
Blood, The Journal of the American Society of Hematology 124 (14), 2298-2305, 2014
Targeted exon capture and sequencing in sporadic amyotrophic lateral sclerosis
J Couthouis, AR Raphael, R Daneshjou, AD Gitler
PLoS Genet 10 (10), e1004704, 2014
Genotype-Guided Dosing of Vitamin K Antagonists (Dr. Maitland-Van Der Zee and colleagues reply)
AH Maitland-van Der Zee, A De Boer, VG Manolopoulos
New England Journal of Medicine 370 (18), 1765-1766, 2014
Pathway analysis of genome-wide data improves warfarin dose prediction
R Daneshjou, NP Tatonetti, KJ Karczewski, H Sagreiya, S Bourgeois, ...
BMC genomics 14 (3), 1-12, 2013
Working toward precision medicine: Predicting phenotypes from exomes in the Critical Assessment of Genome Interpretation (CAGI) challenges
R Daneshjou, Y Wang, Y Bromberg, S Bovo, PL Martelli, G Babbi, ...
Human mutation 38 (9), 1182-1192, 2017
PharmGKB summary: very important pharmacogene information for CYP4F2
ML Alvarellos, K Sangkuhl, R Daneshjou, M Whirl-Carrillo, RB Altman, ...
Pharmacogenetics and genomics 25 (1), 41, 2015
PATH-SCAN: a reporting tool for identifying clinically actionable variants
R Daneshjou, Z Zappala, K Kukurba, SM Boyle, KE Ormond, TE Klein, ...
Biocomputing 2014, 229-240, 2014
Pharmacogenomics and big genomic data: from lab to clinic and back again
A Lavertu, G McInnes, R Daneshjou, M Whirl-Carrillo, TE Klein, ...
Human molecular genetics 27 (R1), R72-R78, 2018
Cohort-specific imputation of gene expression improves prediction of warfarin dose for African Americans
A Gottlieb, R Daneshjou, M DeGorter, S Bourgeois, PJ Svensson, ...
Genome medicine 9 (1), 1-9, 2017
Population‐specific single‐nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans
R Daneshjou, LH Cavallari, PE Weeke, KJ Karczewski, K Drozda, ...
Molecular genetics & genomic medicine 4 (5), 513-520, 2016
Pernio-like eruption associated with COVID-19 in skin of color
R Daneshjou, J Rana, M Dickman, JM Yost, A Chiou, J Ko
JAAD Case Reports 6 (9), 892-897, 2020
Genome-wide meta-analysis identifies eight new susceptibility loci for cutaneous squamous cell carcinoma
KY Sarin, Y Lin, R Daneshjou, A Ziyatdinov, G Thorleifsson, A Rubin, ...
Nature communications 11 (1), 1-8, 2020
Twitter journal clubs: medical education in the era of social media
R Daneshjou, AS Adamson
JAMA dermatology 156 (7), 729-730, 2020
Predicting venous thromboembolism risk from exomes in the Critical Assessment of Genome Interpretation (CAGI) challenges
G McInnes, R Daneshjou, P Katsonis, O Lichtarge, R Srinivasan, S Rana, ...
Human mutation 40 (9), 1314-1320, 2019
Pharmacogenomics in dermatology: tools for understanding gene-drug associations
R Daneshjou, R Huddart, T Klein, R Altman
Seminars in cutaneous medicine and surgery 38 (1), E19, 2019
Population-specific imputation of gene expression improves prediction of pharmacogenomic traits for African Americans
A Gottlieb, R Daneshjou, M DeGorter, SB Montgomery, RB Altman
BioRxiv, 115451, 2017
The system can't perform the operation now. Try again later.
Articles 1–20